Home
KYMR
KYMR News

Latest Kymera Therapeutics Inc. (KYMR) News on July 27, 2024

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn

Simply Wall St.

a day ago

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Zacks

15 days ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Zacks

16 days ago

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Why Kymera Therapeutics Stock Is Soaring Today

Motley Fool

17 days ago

Why Kymera Therapeutics Stock Is Soaring Today

Investing.com

17 days ago

Kymera Therapeutics soars as Sanofi expands phase 2 trials

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Investopedia

17 days ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

Zacks

17 days ago

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

MT Newswires

17 days ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $36 From $31, Maintains Neutral Rating

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

GlobeNewswire

18 days ago

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

MT Newswires

18 days ago

Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

GlobeNewswire

18 days ago

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire

a month ago

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

2 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

2 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

2 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

2 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

2 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

2 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

2 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

2 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

2 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

2 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

2 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

2 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

2 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

2 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

2 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

2 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire

2 months ago

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire

2 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire

2 months ago

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

GlobeNewswire

2 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire

2 months ago

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire

3 months ago

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

3 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks

3 months ago

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

Zacks

3 months ago

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

MT Newswires

3 months ago

Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53

GuruFocus.com

3 months ago

Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

MT Newswires

3 months ago

Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

3 months ago

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

3 months ago

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks

3 months ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

20 Counties with the Highest Cancer Rates in the US

Insider Monkey

3 months ago

20 Counties with the Highest Cancer Rates in the US

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

GlobeNewswire

3 months ago

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

GlobeNewswire

5 months ago

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

GuruFocus.com

5 months ago

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher

Simply Wall St.

5 months ago

Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

5 months ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts

Simply Wall St.

5 months ago

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Kymera Therapeutics Inc Earnings Call

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results

GuruFocus.com

5 months ago

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire

5 months ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR)

GuruFocus.com

5 months ago

Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR)

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zacks

5 months ago

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

5 months ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

GlobeNewswire

5 months ago

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc

GuruFocus.com

6 months ago

Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

GlobeNewswire

6 months ago

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Barrons.com

6 months ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

Motley Fool

6 months ago

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

Motley Fool

6 months ago

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

Oracle (ORCL) Opens OCI Generative AI Service for Enterprises

Zacks

6 months ago

Oracle (ORCL) Opens OCI Generative AI Service for Enterprises

Is Waste Management (NYSE:WM) Using Too Much Debt?

Simply Wall St.

6 months ago

Is Waste Management (NYSE:WM) Using Too Much Debt?

ACV to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024

GlobeNewswire

6 months ago

ACV to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024

Cathie Wood Stocks In 2024: Tesla Stock Rises Ahead Of Earnings

Investor's Business Daily

6 months ago

Cathie Wood Stocks In 2024: Tesla Stock Rises Ahead Of Earnings

Patria Announces Fourth Quarter & Full Year 2023 Investor Call

GlobeNewswire

6 months ago

Patria Announces Fourth Quarter & Full Year 2023 Investor Call

Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc

GuruFocus.com

6 months ago

Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc

Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

6 months ago

Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?

AGNC Investment (AGNC) Q4 Earnings Beat Estimates

Zacks

6 months ago

AGNC Investment (AGNC) Q4 Earnings Beat Estimates

InterDigital (IDCC) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

6 months ago

InterDigital (IDCC) Surpasses Market Returns: Some Facts Worth Knowing

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN

Zacks

6 months ago

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN

Is H&E Equipment Services (HEES) Stock Undervalued Right Now?

Zacks

6 months ago

Is H&E Equipment Services (HEES) Stock Undervalued Right Now?

NielsenIQ and TransUnion Collaborate to Enable Targeted Advertising with First-Party Retail Purchase Data

Business Wire

6 months ago

NielsenIQ and TransUnion Collaborate to Enable Targeted Advertising with First-Party Retail Purchase Data

Spotting Winners: Spectrum Brands (NYSE:SPB) And Household Products Stocks In Q3

StockStory

6 months ago

Spotting Winners: Spectrum Brands (NYSE:SPB) And Household Products Stocks In Q3

Ambarella (AMBA) Collaborates With e-con Systems to Launch RCP

Zacks

6 months ago

Ambarella (AMBA) Collaborates With e-con Systems to Launch RCP

5 Value Stocks With Impressive EV-to-EBITDA Ratios to Scoop Up

Zacks

6 months ago

5 Value Stocks With Impressive EV-to-EBITDA Ratios to Scoop Up

Thermo Fisher Scientific (TMO) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

6 months ago

Thermo Fisher Scientific (TMO) Stock Slides as Market Rises: Facts to Know Before You Trade

3 Stocks to Profit from the Enormous Gig Economy

InvestorPlace

6 months ago

3 Stocks to Profit from the Enormous Gig Economy

The GoodRx Effect: Delivering a Transformative Impact on the U.S. Healthcare System through Prescription Savings

Business Wire

6 months ago

The GoodRx Effect: Delivering a Transformative Impact on the U.S. Healthcare System through Prescription Savings

Livanova to close loss-making circulatory support business

MedTech Dive

7 months ago

Livanova to close loss-making circulatory support business

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

GlobeNewswire

7 months ago

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

With 74% ownership of the shares, Global Net Lease, Inc. (NYSE:GNL) is heavily dominated by institutional owners

Simply Wall St.

7 months ago

With 74% ownership of the shares, Global Net Lease, Inc. (NYSE:GNL) is heavily dominated by institutional owners

Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?

Zacks

7 months ago

Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?

Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Business Wire

7 months ago

Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Do MYR Group's (NASDAQ:MYRG) Earnings Warrant Your Attention?

Simply Wall St.

7 months ago

Do MYR Group's (NASDAQ:MYRG) Earnings Warrant Your Attention?

TransAlta (TAC) Stock Dips While Market Gains: Key Facts

Zacks

7 months ago

TransAlta (TAC) Stock Dips While Market Gains: Key Facts

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering

Investor's Business Daily

7 months ago

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering

Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

7 months ago

Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Kymera Therapeutics Announces Proposed Public Offering

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Proposed Public Offering

Atour Lifestyle Holdings Limited's (NASDAQ:ATAT) largest shareholders are private equity firms with 32% ownership, insiders own 29%

Simply Wall St.

7 months ago

Atour Lifestyle Holdings Limited's (NASDAQ:ATAT) largest shareholders are private equity firms with 32% ownership, insiders own 29%

Reuters

7 months ago

UPDATE 1-Vermilion Energy employee agrees to pay hefty penalty for insider trading

Reuters

7 months ago

Vermilion Energy employee pays C$400,000 to Alberta regulator for insider trading

Should You Buy Vermilion Energy Inc. (TSE:VET) For Its Upcoming Dividend?

Simply Wall St.

7 months ago

Should You Buy Vermilion Energy Inc. (TSE:VET) For Its Upcoming Dividend?

Global Net Lease, Inc. Announces Preferred Stock Dividends

GlobeNewswire

7 months ago

Global Net Lease, Inc. Announces Preferred Stock Dividends

Share on Social Networks: